| scholarly article | Q13442814 |
| P50 | author | Dyfrig A. Hughes | Q40943753 |
| Kalifa A Bojang | Q42305767 | ||
| Julie A. Simpson | Q47172274 | ||
| Steve Ward | Q55112735 | ||
| Christine Manyando | Q85982640 | ||
| P2093 | author name string | Leon Aarons | |
| Peter Winstanley | |||
| Geoffrey Edwards | |||
| William A Watkins | |||
| P2860 | cites work | Developmental aspects of human hepatic drug glucuronidation in young children and adults | Q28344957 |
| Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster | Q29614923 | ||
| Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. | Q33749505 | ||
| Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children | Q33977967 | ||
| Nonlinear mixed effects models for repeated measures data | Q34198168 | ||
| How can we do pharmacokinetic studies in the tropics? | Q34387231 | ||
| The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria | Q34402882 | ||
| Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria | Q37739425 | ||
| Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial | Q38870092 | ||
| The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy | Q38882717 | ||
| The search for synergy: a critical review from a response surface perspective. | Q40417895 | ||
| Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine | Q41912638 | ||
| The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses | Q41913682 | ||
| Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites | Q43409079 | ||
| Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection | Q43673163 | ||
| Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses | Q45040293 | ||
| Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range | Q46154949 | ||
| A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil | Q47900426 | ||
| Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes | Q73846452 | ||
| All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes | Q74094338 | ||
| Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins | Q77228680 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| antimalarial | Q521616 | ||
| pharmacodynamics | Q725307 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 289-300 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone | |
| P478 | volume | 61 |
| Q28477853 | A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial |
| Q21143739 | Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria |
| Q28473083 | Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants |
| Q33726415 | Formation and identification of a degradant in chlorproguanil–dapsone–artesunate (Dacart™) tablets |
| Q36832446 | Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development |
| Q37207985 | Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants |
| Q28534820 | Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum |
| Q26830528 | Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization |
| Q37257896 | Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs |
| Q45973898 | Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. |
| Q46990184 | Population pharmacokinetics of valproate in Chinese children with epilepsy |
| Q40187269 | Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations |
| Q34894294 | The effect of intermittent preventive treatment on anti-malarial drug resistance spread in areas with population movement |
Search more.